Teva and MedinCell report positive data from schizophrenia trial
Time to impending relapse was the trial’s primary endpoint. Credit: Jochen Pippir from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
